Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

that of nocturia which may result from other conditions such as overactive bladder.

About VA111913 and dysmenorrhoea:

VA111913 is an oral small molecule drug candidate in Phase I clinical development for prevention and treatment of dysmenorrhoea, a condition characterized by abnormal contractions of the uterus during menstruation causing severe pain. VA111913 acts by blocking vasopressin 1a receptors in smooth muscle in the uterus wall, which in response to elevated vasopressin levels leads to dysmenorrhoea. VA111913 has demonstrated in preclinical trials it can normalise smooth muscle contraction thereby offering the potential for it to be the first licensed drug that directly targets the cause of this condition in the uterus.

A Phase I trial with VA111913 is underway and expected to report during H1 2009, with Phase II proof of concept studies expected to start in H2 2009, involving up to 150 patients and completing in H2 2010.

Dysmenorrhoea affects a large number of women for whom there are currently no targeted therapies; treatments that are in common use however include over-the-counter painkillers (e.g. naproxen or ibuprofen) or oral contraceptives used 'off-label'. It is estimated that the market opportunity for a targeted drug for the prophylaxis and treatment of dysmenorrhoea is approximately US$1 billion per year.

    Contact details:


    Vantia Therapeutics

    Dr Jim Phillips, CEO              +44(0)238-076-3433
    ir@vantiatherapeutics.com         +44(0)7515-397176


    Citigate Dewe Rogerson
    Chris Gardner / Mark Swallow / Helena Galilee
    +44(0)207-638-9571
    chris.gardner@citigatedr.co.uk / mark.swallow@citigatedr.co.uk /
    helena.galilee@citigatedr.c
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... (PRWEB) June 03, 2015 Photo-Eyewear™ ( ... its name to PogoTec™, Inc. ( http://www.PogoTec.com ) ... electronic wearable device products and technologies it is developing ... of three business divisions, PogoTec™ will provide focused resources ... as follows: , , On-Track™ – ...
(Date:6/3/2015)... and London (PRWEB) June 03, 2015 ... recently set a new world record by scaling ... on the Blue Waters supercomputer. , STAR-CCM+ ... across many industries to stimulate innovation and lower ... Sector Program and Blue Waters manufacturer Cray to ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Global ... Training, Inc. have announced plans to conduct Romania’s first ... 2015. Through an alliance with Miami-based Stem Cell Training, ... conduct the Adipose and Bone Marrow Stem Cell Training ... a reconstructive plastic surgery specialist practicing in Bucharest and ...
(Date:6/3/2015)... Charlotte, NC (PRWEB) June 03, 2015 ... announce the issuance of US Patent No. 9,044,273, ... on improving the thoraco-lumbar spinal fusion implant procedure ... replacing them with one easy-to-use disposable instrument tray. ... provide for numerous benefits over previous technology. Intelligent ...
Breaking Biology Technology:Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 2NCSA Scales CD-adapco’s STAR-CCM+ to New World Record of 102,000 Cores on Blue Waters 3Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 2Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 3Intelligent Implant Systems Announces US Patent Attained for Revolution™ Spinal System 2
... 31 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ... in the manufacture, research, development, marketing and,distribution of ... four patents to the State Intellectual Property Office ... These applications are patents for a ...
... Ueno, Ltd. announced on July 29 after discussing its R&D policy ... day and determined the R&D items as follows. , , ... ophthalmologic & dermatological fields that are its priority and exclusive areas, ... 1. Development code UF-021 (eye diseases) , , ...
... , , PHILADELPHIA, July 30 eResearchTechnology, Inc. (ERT), ... and other services to the biopharmaceutical, medical device and related industries, announced ... 2009. Unless otherwise noted, all comparative numbers refer to changes from ... , Highlights of the second quarter of 2009 were: ...
Cached Biology Technology:China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations 2China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations 3R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3ERT Reports Second Quarter 2009 Results 2ERT Reports Second Quarter 2009 Results 3ERT Reports Second Quarter 2009 Results 4ERT Reports Second Quarter 2009 Results 5ERT Reports Second Quarter 2009 Results 6ERT Reports Second Quarter 2009 Results 7ERT Reports Second Quarter 2009 Results 8ERT Reports Second Quarter 2009 Results 9ERT Reports Second Quarter 2009 Results 10ERT Reports Second Quarter 2009 Results 11ERT Reports Second Quarter 2009 Results 12
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/21/2015)... -- High crime rate, increasing government ... control systems market in Saudi Arabia ... report by TechSci Research " Saudi Arabia Access Control Systems Market ... market in Saudi Arabia is ... systems market in the Kingdom is growing at a ...
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... the Ohio State University have developed a rapid, multiplexed ... that affect warfarin dose. The related report by ... Drug Response by SELDI-TOF Mass Spectrometry," appears in the ... Diagnostics . Warfarin is an anti-coagulant that is ...
... A comprehensive drug development strategy that starts with extensive ... to a small-molecule prototype has yielded two potential drugs ... led by scientists at The University of Texas M. ... back-to-back online at the Proceedings of the National ...
... explosions and enforce the world,s nuclear test-ban treaty now ... Northern Mariana Islands near Guam. The island of Guam ... of U.S. military forces in the Western Pacific. ... and Southern Methodist University in Dallas will use infrasound ...
Cached Biology News:New strategy develops 2 prototype drugs against cancer, retinal diseases 2New strategy develops 2 prototype drugs against cancer, retinal diseases 3Volcano monitoring will target hazard threat to Marianas, US military and commercial jets 2Volcano monitoring will target hazard threat to Marianas, US military and commercial jets 3Volcano monitoring will target hazard threat to Marianas, US military and commercial jets 4
... and antibody-based immunoaffinity matrices, such as ... times without compromising antigen-antibody reactivity, the ... agents has precluded the application of ... The CHEMICON Re-Blot Plus Western Blot ...
Applications: Western blotting ...
...
... efficiencies and the chemistry of light production ... benefit that they require simple triggering conditions ... This benefit has been exploited to great ... compounds can also be easily modified to ...
Biology Products: